<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04604873</url>
  </required_header>
  <id_info>
    <org_study_id>IC 2019-08</org_study_id>
    <nct_id>NCT04604873</nct_id>
  </id_info>
  <brief_title>The Integrated Support and Palliative in Cancer Day-care Hospital for Patients With Advanced Cancers: Impact on Quality of Life, Care Pathways and Support for Caregivers (HDJ-SPI)</brief_title>
  <official_title>The Integrated Support and Palliative in Cancer Day-care Hospital for Patients With Advanced Cancers: Impact on Quality of Life, Care Pathways and Support for Caregivers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Curie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective is to show the impact on the quality of life (QoL) for adults patients&#xD;
      with advanced cancer managed in day hospital of integrated palliative care of cancer center&#xD;
      (HDJ-SPI).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 28, 2020</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Analyse impact of hospital day care in integrated palliative care department on quality of life of adult patients with advanced stage cancer</measure>
    <time_frame>12 months</time_frame>
    <description>Analyse impact of hospital day care in integrated palliative care department on quality of life of adult patients with advanced stage cancer&#xD;
Outcome shall be evaluated by assessing Survival without quality of life deterioration,measured by EORTC QLQ-C30 scale with monthly evaluation targeting three dimensions :&#xD;
global quality of life/ fatigue/ patient emotional state</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Cancer, Advanced</condition>
  <arm_group>
    <arm_group_label>No hospital one day care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No hospital one day care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hospital one day care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Hospital one day care</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hospital day care follow-up</intervention_name>
    <description>Regular follow up every month in hospital day care</description>
    <arm_group_label>Hospital one day care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient ≥ 18 years old with advanced solid tumor&#xD;
&#xD;
          2. Addressed for the first time to the palliative care team according to current criteria&#xD;
             (medico-psycho-social symptoms, progressive risks)&#xD;
&#xD;
          3. With or without anti-cancer treatment&#xD;
&#xD;
          4. With estimated life expectancy of more than 2 months and less than 12 months&#xD;
&#xD;
          5. Able to communicate in French and answer questionnaires&#xD;
&#xD;
          6. Affiliated with a social security system&#xD;
&#xD;
          7. Having signed informed consent, co-signed by the partner if designated by the patient&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient with primitive brain tumor or malignant hemopathy&#xD;
&#xD;
          2. Severe psychopathological disorders&#xD;
&#xD;
          3. Pregnant patient or childbearing potential without effective method of birth control&#xD;
&#xD;
          4. Unable to be followed at the cancer center until death&#xD;
&#xD;
          5. Patient deprived of liberty or under guardianship -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie MORIN, MD</last_name>
      <phone>05.56.33.33.33</phone>
      <email>s.morin@bordeaux.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Sophie MORIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elise GILBERT, MD</last_name>
      <phone>0492031596</phone>
      <email>elise.gilbert@nice.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Elise GILBERT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institutcurie Paris</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CAROLE BOULEUC, MD</last_name>
      <phone>0144324640</phone>
      <email>carole.bouleuc@curie.fr</email>
    </contact>
    <investigator>
      <last_name>Carole BOULEUC, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>INSTITUT CURIE Saint-Cloud</name>
      <address>
        <city>Saint-cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabeth ANGELLIER, MD</last_name>
      <phone>0147112380</phone>
      <email>elisabeth.angellier@curie.fr</email>
    </contact>
    <investigator>
      <last_name>Elisabeth ANGELLIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Véronique FRASIE, MD</last_name>
      <phone>0368767492</phone>
      <email>vfrasie@icans.eu</email>
    </contact>
    <investigator>
      <last_name>Véronique FRASIE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 20, 2020</study_first_submitted>
  <study_first_submitted_qc>October 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2020</study_first_posted>
  <last_update_submitted>April 30, 2021</last_update_submitted>
  <last_update_submitted_qc>April 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

